Streetbeat News

Products Services

PODD

Insulet's shares have risen following the announcement that its Omnipod device is now approved for use by people with type 2 diabetes in the US.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2024 | 5:59 pm

TCBP

TC BioPharm has been granted a European patent for the use of modified gamma delta cells in treating cancer and viral indications. This development could enhance their therapeutic offerings and market position.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2024 | 5:51 pm

META

Meta is considering the development of mixed reality glasses, code-named 'Puffin'. This move indicates Meta's continued investment in augmented and virtual reality technologies.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2024 | 5:49 pm

BA

ITA

LMT

NOC

PPA

XAR

Nine Palestinians were killed as Israeli forces conducted major raids in the West Bank, escalating tensions in the region. Defense stocks showed mixed performance, with Lockheed Martin gaining and Boeing slipping.

Portfolio Pulse from Michael Juliano

August 28, 2024 | 5:45 pm

HKMPF

JAZZ

Jazz Pharmaceuticals and Hikma Pharmaceuticals are facing allegations of delaying a generic version of Jazz's narcolepsy drug, Xyrem, to maintain high prices. The case will proceed to trial, with claims of antitrust violations and price increases. Jazz denies the allegations, citing regulatory approval of its distribution strategy.

Portfolio Pulse from Vandana Singh

August 28, 2024 | 5:37 pm

ANF

BABA

CPRI

F

PDD

SBUX

TSCO

TSLA

W

WYNN

The article highlights unusual options activity for 10 consumer discretionary stocks, indicating potential trading opportunities. Notable mentions include bullish sentiment for TSLA, SBUX, ANF, F, W, and CPRI, and bearish sentiment for BABA, PDD, WYNN, and TSCO.

Portfolio Pulse from Benzinga Insights

August 28, 2024 | 5:35 pm

JNJ

The American Hospital Association (AHA) is urging the Health Resources and Services Administration (HRSA) to take enforcement action against Johnson & Johnson (J&J) for changing its 340B Drug Pricing Program model. J&J plans to replace upfront discounts with a rebate model for drugs like Stelara and Xarelto, potentially impacting hospital finances and patient access.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2024 | 5:33 pm

NAMS

Needham has initiated coverage on NewAmsterdam Pharma (NASDAQ:NAMS), highlighting its cholesterol drug obicetrapib as a potential blockbuster. The drug showed significant LDL-C reduction in trials, and Needham has set a Buy rating with a $36 price target. Obicetrapib could generate over $2 billion in sales, targeting 30 million patients.

Portfolio Pulse from Vandana Singh

August 28, 2024 | 5:33 pm

DELL

Dell Technologies is set to release its Q2 earnings, with a focus on AI-powered computing and margins. Analysts expect revenue of $24.14 billion and EPS of $1.71. Dell has a history of beating estimates and its stock is up 46% YTD. Analysts are optimistic about AI server demand and cost cuts improving margins.

Portfolio Pulse from Chris Katje

August 28, 2024 | 5:32 pm

SMCI

Super Micro Computer is currently presenting at the Deutsche Bank Technology Conference, which could provide insights into the company's future strategies and performance.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2024 | 5:10 pm